Patents by Inventor Christian Sirrenberg

Christian Sirrenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190365896
    Abstract: Combination therapy for the treatment of cancer.
    Type: Application
    Filed: December 18, 2017
    Publication date: December 5, 2019
    Inventors: Lars Damstrup, Thomas Grombacher, Christian Sirrenberg, Lyubomir Vassilev, Astrid Zimmermann
  • Patent number: 9725446
    Abstract: Compounds of the formula (I) in which R, R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed for the treatment of tumors.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: August 8, 2017
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Christian Sirrenberg, Thomas J. J. Mueller, Eugen Merkul, Gnuni Amatunu Karapetyan
  • Publication number: 20160130269
    Abstract: Compounds of the formula (I) in which R, R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed for the treatment of tumors.
    Type: Application
    Filed: January 5, 2016
    Publication date: May 12, 2016
    Applicant: MERCK PATENT GmbH
    Inventors: Dieter DORSCH, Christian SIRRENBERG, Thomas J.J. MUELLER, Eugen MERKUL, Gnuni Amatunu KARAPETYAN
  • Patent number: 9266887
    Abstract: Compounds of the formula (I) in which R, R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed for the treatment of tumors.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: February 23, 2016
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Christian Sirrenberg, Thomas J. J. Mueller, Eugen Merkul, Gnuni Amatunu Karapetyan
  • Publication number: 20150152104
    Abstract: Compounds of the formula (I) in which R, R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed for the treatment of tumours.
    Type: Application
    Filed: February 6, 2015
    Publication date: June 4, 2015
    Applicant: MERCK PATENT GMBH
    Inventors: Dieter DORSCH, Christian SIRRENBERG, Thomas J.J. MUELLER, Eugen MERKUL, Gnuni Amatunu KARAPETYAN
  • Patent number: 8981101
    Abstract: Compounds of the formula (I) in which R, R1, R2 and R3 have the meanings indicated in claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed for the treatment of tumors.
    Type: Grant
    Filed: January 9, 2012
    Date of Patent: March 17, 2015
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Christian Sirrenberg, Thomas J. J. Mueller, Eugen Merkul, Gnuni Amatunu Karapetyan
  • Patent number: 8906930
    Abstract: Novel quinazolinamide derivatives of the formula (I), in which R1-R4 and X have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
    Type: Grant
    Filed: October 26, 2010
    Date of Patent: December 9, 2014
    Assignee: Merck Patent GmbH
    Inventors: Hans Michael Eggenweiler, Christian Sirrenberg, Hans Peter Buchstaller
  • Patent number: 8816070
    Abstract: 5-[4-(2-Methylphenyl)-3-hydroxy-4H-1,2,4-triazol-5-yl]-2,4-dihydroxy-N-methyl-N-butylbenzamide is an HSP90 inhibitor and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
    Type: Grant
    Filed: December 11, 2007
    Date of Patent: August 26, 2014
    Assignee: Merck Patent GmbH
    Inventors: Hans Michael Eggenweiler, Michael Wolf, Hans Peter Buchstaller, Christian Sirrenberg
  • Patent number: 8791129
    Abstract: Novel quinazolinamide derivatives of the formula (I), in which R1-R43 and X have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: July 29, 2014
    Assignee: Merck Patent GmbH
    Inventors: Hans-Michael Eggenweiler, Christian Sirrenberg, Hans-Peter Buchstaller
  • Patent number: 8722903
    Abstract: Novel indazole derivatives of the formula (I), in which R1-R3 have the meanings indicated in Claim (1), are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
    Type: Grant
    Filed: June 18, 2007
    Date of Patent: May 13, 2014
    Assignee: Merck Patent GmbH
    Inventors: Hans-Peter Buchstaller, Hans-Michael Eggenweiler, Michael Wolf, Christian Sirrenberg
  • Publication number: 20130310391
    Abstract: Compounds of the formula (I) in which R, R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed for the treatment of tumours.
    Type: Application
    Filed: January 9, 2012
    Publication date: November 21, 2013
    Applicant: MERCK PATENT GMBH
    Inventors: Dieter Dorsch, Christian Sirrenberg, Thomas J.J. Mueller, Eugen Merkul, Gnuni Amatunu Karapetyan
  • Patent number: 8546390
    Abstract: Compounds of the formula (I), in which R1, R2, R3 and R4 have the meanings indicated in claim (1), are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumors.
    Type: Grant
    Filed: May 23, 2008
    Date of Patent: October 1, 2013
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Margarita Wucherer-Plietker, Lars T. Burgdorf, Christian Sirrenberg, Christina Esdar, Thomas J. J. Mueller, Eugen Merkul
  • Patent number: 8546565
    Abstract: Novel quinazolinamide derivatives of the formula (I), in which R1-R5 and X have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: October 1, 2013
    Assignee: Merck Patent Gesellschaft
    Inventors: Hans-Michael Eggenweiler, Christian Sirrenberg, Hans-Peter Buchstaller
  • Patent number: 8501754
    Abstract: Novel quinazolinamide derivatives of the formula (I), in which R1-R3 have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: August 6, 2013
    Assignee: MERCK PATENT GmbH
    Inventors: Hans-Michael Eggenweiler, Christian Sirrenberg, Hans-Peter Buchstaller
  • Publication number: 20130178443
    Abstract: Novel quinazolinamide derivatives of the formula (I), in which R1-R43 and X have the meanings indicated in claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
    Type: Application
    Filed: August 31, 2011
    Publication date: July 11, 2013
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Hans-Michael Eggenweiler, Christian Sirrenberg, Hans-Peter Buchstaller
  • Patent number: 8410143
    Abstract: The present invention relates to methylene urea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.
    Type: Grant
    Filed: June 19, 2009
    Date of Patent: April 2, 2013
    Assignee: Merck Patent GmbH
    Inventors: Hans-Peter Buchstaller, Matthias Wiesner, Oliver Schadt, Christiane Amendt, Frank Zenke, Christian Sirrenberg, Matthias Grell, Dirk Finsinger
  • Patent number: 8304416
    Abstract: Novel compounds of the formula I in which R1, R2, R3 and Het are as defined herein, which are inhibitors of tyrosine kinases and/or Raf kinases and can be employed for the treatment of tumors, for neuroprotection and for protection of the stress proteins of the skin.
    Type: Grant
    Filed: February 15, 2011
    Date of Patent: November 6, 2012
    Assignee: Merck Patent GmbH
    Inventors: Teresa Mujica-Fernaud, Herwig Buchholz, Wilfried Rautenberg, Christian Sirrenberg
  • Patent number: 8293891
    Abstract: Compounds of the formula (I), in which R1, R2, R3, R4 and R5 have the meanings indicated in claim 1, are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumors.
    Type: Grant
    Filed: January 28, 2008
    Date of Patent: October 23, 2012
    Assignee: Merck Patent Gesellschaft mit Beschrankter Haftung
    Inventors: Dieter Dorsch, Christian Sirrenberg, Thomas J. J. Mueller, Eugen Merkul
  • Publication number: 20120264999
    Abstract: Compounds of the formula (I), in which R1, R2, R3, R4 and R5 have the meanings indicated in claim 1, are inhibitors of cell proliferation/|cell vitality and can be employed for the treatment of tumours
    Type: Application
    Filed: June 19, 2012
    Publication date: October 18, 2012
    Applicant: Merck Patent Gesellschaft
    Inventors: Dieter Dorsch, Christian Sirrenberg, Thomas J.J Mueller, Eugen Merkul
  • Publication number: 20120238582
    Abstract: Novel quinazolinamide derivatives of the formula (I), in which R1-R4 and X have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
    Type: Application
    Filed: October 26, 2010
    Publication date: September 20, 2012
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER hAFTUNG
    Inventors: Hans Michael Eggenweiler, Christian Sirrenberg, Hans Peter Buchstaller